Atrial fibrillation ablation compared to pacemaker therapy in patients with tachycardia–bradycardia syndrome: A systematic review and updated meta-analysis
Open Access
- 19 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (16) , e37543
Abstract
Background: Tachycardia–bradycardia syndrome (TBS) is a subtype of sick sinus syndrome characterized by prolonged sinus pause (≥3 s) following termination of tachyarrhythmias, primarily atrial fibrillation (AF). There is controversy regarding whether the long-term prognosis of AF ablation is superior to pacemaker implantation. This study aimed to compare the effects of AF ablation and pacemaker therapy in patients with TBS. Methods: We conducted a comprehensive search of electronic databases, including PubMed, Cochrane, EmBase, Web of Science, and Chinese BioMedical, up until December 1, 2023. We included studies that reported the effects of AF ablation vs pacemaker therapy in patients with TBS. From this search, we identified 5 studies comprising 843 participants with TBS who underwent catheter AF ablation or pacemaker therapy. Results: Our meta-analysis revealed that AF ablation and pacemaker therapy had similar effects on cardiovascular death (odds ratio [OR] = 0.62 and 95% confidence interval [CI]: 0.14–2.65), procedural complications (OR = 1.53 and 95% CI: 0.67–3.48), and cardiovascular rehospitalization (OR = 0.57 and 95% CI: 0.26–1.22). However, AF ablation provided greater benefits than pacemaker therapy in terms of all-cause mortality (OR = 0.37 and 95% CI: 0.17–0.82), thromboembolism (OR = 0.25 and 95% CI: 0.12–0.49), stroke (OR = 0.28 and 95% CI: 0.13–0.57), heart failure (OR = 0.27 and 95% CI: 0.13–0.56), freedom from AF (OR = 23.32 and 95% CI: 7.46–72.92), and prevention of progression to persistent AF (OR = 0.12 and 95% CI: 0.06–0.24). Furthermore, AF ablation resulted in a reduced need for antiarrhythmic agents (OR = 0.21 and 95% CI: 0.08–0.59). Conclusion: AF ablation can effectively reduce the risk of all-cause mortality, thromboembolism, stroke, heart failure, and progression to persistent AF in patients with TBS. Additionally, it may eliminate the need for further pacemaker therapy in most cases after ablation. Therefore, AF ablation is considered superior to pacemaker therapy in the management of patients with TBS.Keywords
This publication has 27 references indexed in Scilit:
- DELAY IN ATRIAL FIBRILLATION ABLATION FOR WOMEN WITH SINUS NODE DYSFUNCTION AND A HIGHER INCIDENCE OF THE NEED FOR PACEMAKER IMPLANTATIONJACC, 2022
- Long-term effect of catheter ablation on tachycardia-bradycardia syndrome: evidenced by 10 years follow upActa Cardiologica, 2019
- Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular PacingJACC, 2018
- 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summaryHeart Rhythm, 2017
- Single lead atrial vs. dual chamber pacing in sick sinus syndrome: extended register-based follow-up in the DANPACE trialEP Europace, 2016
- Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohortEP Europace, 2016
- The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-upEP Europace, 2013
- Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological researchJournal of Evaluation in Clinical Practice, 2012
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000